Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5mg 17 β-estradiol and 2.5mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms
Hormone replacement therapy (HRT) is the most effective treatment for vasomotor symptoms associated with menopause and may improve quality of life [1]. HRT is also effective for the prevention of postmenopausal osteoporosis [2]. Multiple HRT combinations are available. The individual drugs and their combination are important in determining their safety and efficacy. It is recognised that different progestogens [3], and estrogens have distinct properties. Guidelines recommend individualising and tailoring HRT according to symptoms and the need for prevention, as well as age, personal and family history, and the woman ’s preferences and expectations using the lowest effective dose of estrogen to treat these symptoms [1,4,5].
Source: Maturitas - Category: Primary Care Authors: Sophia Tsiligiannis, Bettina C. Wick-Urban, Jan van der Stam, John C. Stevenson Source Type: research
More News: Estradiol | Hormone Replacement Therapy | Hormones | Men | Menopause | Orthopaedics | Osteoporosis | Primary Care | Women